Guidance
We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.
NICE advice
Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
Published advice on this topic (5)
- New advice in the last 6 months (0)
- Updated advice in the last 6 months (0)
- In development advice (0)
Quality standards
Set out priority areas for quality improvement in health and social care.
Published quality standards on this topic (2)
- New quality standards in the last 6 months (0)
- Updated quality standards in the last 6 months (0)
- In development quality standards (0)
NICE Pathways
Interactive topic-based flowcharts that allow you to navigate our recommendations on any subject.
Guidance by programme
-
NICE guidelines (3)
Review the evidence across broad health and social care topics.
-
Technology appraisal guidance (100)
Review clinical and cost effectiveness of new treatments.
-
Diagnostics guidance (2)
Review new diagnostic technologies for adoption in the NHS.
-
Interventional procedures guidance (7)
Assessments of whether procedures are safe enough and work well enough for wider use in the NHS.
Advice by programme
-
Evidence summaries (2)
Review the best available evidence for selected medicines.
-
Medtech innovation briefings (3)
Review the evidence and likely costs of medical devices and technologies.
Products being developed or updated
-
In development (31)
Guidance, quality standards and advice being developed.
-
Proposed (1)
Technology appraisal guidance which has been proposed for development.
NICE Pathways
Interactive topic-based flowcharts that allow you to navigate our recommendations on any subject. Find out more about NICE Pathways.
NICE guidelines
Review the evidence across broad health and social care topics.
-
Brain tumours (primary) and brain metastases in adults (NG99)
-
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)
-
Metastatic spinal cord compression in adults: risk assessment, diagnosis and management (CG75)
Quality standards
Set out priority areas for quality improvement in health and social care.
Technology appraisal guidance
Review clinical and cost effectiveness of new treatments.
-
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)
-
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)
-
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310)
-
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)
-
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)
-
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)
-
Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)
-
Avelumab for treating metastatic Merkel cell carcinoma (TA517)
-
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)
-
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)
-
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)
-
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)
-
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)
-
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)
-
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)
-
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)
-
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)
-
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)
-
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)
-
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)
-
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)
-
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)
-
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)
-
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)
-
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)
-
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (TA258)
-
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (TA449)
-
Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)
-
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)
-
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (TA192)
-
Gemcitabine for the treatment of metastatic breast cancer (TA116)
-
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)
-
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)
-
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)
-
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)
-
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)
-
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (TA257)
-
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)
-
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)
-
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (TA347)
-
Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)
-
Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)
-
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)
-
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)
-
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)
-
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)
-
Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (TA416)
-
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)
-
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)
-
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) (TA240)
-
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)
-
Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)
-
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA519)
-
Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)
-
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)
-
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)
-
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)
-
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)
-
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (TA334)
-
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)
-
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)
-
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)
-
Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)
-
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)
-
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)
-
Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)
-
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)
-
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)
Diagnostics guidance
Review new diagnostic technologies for adoption in the NHS.
-
EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)
-
Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)
Interventional procedures guidance
Assessments of whether procedures are safe enough and work well enough for wider use in the NHS.
-
Chemosaturation via percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic liver cancer (IPG488)
-
Cryotherapy for the treatment of liver metastases (IPG369)
-
Cytoreduction surgery followed by hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis (IPG331)
-
Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (IPG446)
-
Irreversible electroporation for treating liver metastases (IPG445)
-
Microwave ablation for treating liver metastases (IPG553)
-
Percutaneous cementoplasty for palliative treatment of bony malignancies (IPG179)
Evidence summaries
Review the best available evidence for selected medicines.
-
Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)
-
Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)
Medtech innovation briefings
Review the evidence and likely costs of medical devices and technologies.
-
Caris Molecular Intelligence for guiding cancer treatment (MIB120)
-
OSNA for colon cancer staging (MIB77)
-
Plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer (MIB137)
In development
-
Abiraterone for the treatment of metastatic, castrate-resistant prostate cancer following previous cytotoxic chemotherapy TA259
-
Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]
-
Atezolizumab for treating metastatic colorectal cancer after 2 therapies [1298]
-
Atezolizumab plus bevacizumab for untreated locally advanced or metastatic renal cell carcinoma [ID1365]
-
Atezolizumab with gemcitabine and carboplatin for treating metastatic urothelial bladder cancer [ID1206]
-
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]
-
Breast cancer (brain metastases) - etirinotecan pegol [ID881]
-
Brigatinib for untreated ALK-positive metastatic non-small-cell lung cancer ID1468
-
Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]
-
Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]
-
Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy ID1172
-
Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169
-
Encorafenib with binimetinib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma [ID923]
-
Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]
-
Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]
-
Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) ID622
-
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]
-
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]
-
Lung cancer (non-small-cell, EGFR T790M-positive, metastatic, treated) - rociletinib [ID883]
-
Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]
-
Nivolumab with ipilimumab for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1332]
-
Nivolumab with ipilimumab for untreated metastatic renal cell carcinoma [ID1182]
-
Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]
-
Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566]
-
Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]
-
Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]
-
Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer ID1168
-
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
-
Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck (ID1140)
-
Pembrolizumab with axitinib for untreated metastatic renal cell carcinoma ID1426
-
Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]
Proposed
New guidance and advice
Guidance and advice added since April 2018
-
Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]
-
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)
-
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)
-
Atezolizumab for treating metastatic colorectal cancer after 2 therapies [1298]
-
Atezolizumab plus bevacizumab for untreated locally advanced or metastatic renal cell carcinoma [ID1365]
-
Brain tumours (primary) and brain metastases in adults (NG99)
-
Brigatinib for untreated ALK-positive metastatic non-small-cell lung cancer ID1468
-
Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]
-
Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy ID1172
-
Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169
-
Encorafenib with binimetinib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma [ID923]
-
Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]
-
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)
-
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)
-
Nivolumab with ipilimumab for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1332]
-
Nivolumab with ipilimumab for untreated metastatic renal cell carcinoma [ID1182]
-
Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]
-
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
-
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA519)
-
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)
-
Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck (ID1140)
-
Pembrolizumab with axitinib for untreated metastatic renal cell carcinoma ID1426
-
Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]
Updated guidance and advice
Guidance and advice updated since April 2018
News on this topic
More people to be given dye to highlight brain tumours to surgeons say NICE
Hundreds of patients a year set to benefit from roll out of dye to all of England’s neurosurgical units
Putting guidance into practice
Shared learning
Examples of how our guidance and standards have been put into practice in the NHS, local authorities, voluntary sector and a range of other organisations.
Showing 1 of 1 shared learning examples for this topic: